Formed to address critical needs for cellular analysis tools in the pharmaceutical, biotech and research industries, Fluxion Biosiences has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition. The firm offers the BioFlux system that enables various cell-based assays in the fields of immunology, vascular biology, microbiology, cancer research, and stem cells; IonFlux system, which provides automated patch clamping for recording from ligand-gated and voltage-gated ion channels; and CytoFlux System that provides cytometric analysis with high-resolution images of adherent or suspension cells. The company also provides ISOFLUX, a rare cell access system that provides unprecedented target cell recovery and complete access to cells for downstream applications; and CrossFlux, an advanced flow cell instrument for in vitro cellular assays, which facilitates a range of cellular assays for stem cell homing, transmigration, blood-brain barrier modeling, invasion/migration, cellular adhesion, cell polarization, therapeutic development, and long term cell culture. Its BioFlux products are used in various applications, including drug discovery, cell biology, and microbiology; and IonFlux systems are used in electrophysiology and ion channel screening, including ion channel drug screening, ion channel pharmacology, safety toxicology, and functional expression and mutant screening.
